Sermonix and Regor Announce Strategic Collaboration to Optimize Regor’s Proprietary rCARD Platform for Identification of Novel Targets and Therapeutics
COLUMBUS, Ohio, and CAMBRIDGE, Mass., March 24 /PRNewswire/ — Sermonix Pharmaceuticals and Regor Therapeutics Group have entered a strategic collaboration. The partnership will utilize Regor’s rCARD™ platform to identify novel targets and therapeutics for metastatic breast cancer, aiming for treatments that balance efficacy with tolerability and quality of life.
Circular Genomics Strengthens Scientific Advisory Board with Addition of Alzheimer’s Disease Expert
Mar. 19, 2025 /Circular Genomics Communications/ — Circular Genomics has appointed Phyllis Ferrell, MBA, DrPH, a recognized expert in Alzheimer’s disease (AD), dementia care, and global health, to its Scientific Advisory Board (SAB). Her expertise will support the company’s development of circular RNA (circRNA) biomarkers for neurological and psychiatric disorders, particularly AD.
Circular Genomics Joins Lilly Gateway Labs in San Diego to Develop Its Best-In-Class Circular RNA Platform for the Diagnosis and Prognosis of Alzheimer’s Disease
Mar. 17, 2025 /Circular Genomics Communications/ — Circular Genomics announced it is moving its headquarters to Lilly Gateway Labs in San Diego. The move aims to accelerate the development of its circular RNA (circRNA) biomarker platform for Alzheimer’s disease diagnostic and prognostic blood tests through collaboration and access to resources.
Count Me In Launches tRCC Patient Research Project
Mar. 11, 2025 /Count Me In Communications/ — Count Me In has launched a new patient-partnered research project focused on translocation renal cell carcinoma (tRCC), a rare kidney cancer. The tRCC Project enables patients to securely share their unique health data and experiences online to accelerate research and the development of new treatments.
AGC Biologics Honored at CDMO Leadership Awards for Excellence in Quality, Biologics and Cell and Gene Therapies
SEATTLE, Mar. 10, 2025 /PRNewswire/ — AGC Biologics announced it has won two 2025 CDMO Leadership Awards, recognizing its global excellence in both Biologics and Cell & Gene therapy services based on surveys of industry leaders.
Stellaromics Secures Significant Funding to Advance 3D Spatial Biology
BOSTON, Feb. 11, 2025 /PRNewswire/ — Stellaromics announced an $80M Series B funding round led by Catalyst4. The investment will support the debut of Pyxa, an innovative platform built on STARmap and RIBOmap technologies that enables detailed 3D analysis of thick tissue samples.
EditCo Bio, Inc. Launches XDel Knockout Cells: Redefining CRISPR Gene Editing Efficiency and Reproducibility
REDWOOD CITY, Calif., Jan. 29, 2025 /BUSINESS WIRE/ — EditCo Bio, a leader in cutting-edge genetic engineering and cellular model solutions, today announced the launch of XDel Knockout Cells, an innovative product designed to revolutionize the field of CRISPR gene editing. By leveraging a groundbreaking guide RNA (gRNA) design strategy, XDel technology ensures robust, reliable, and reproducible gene knockout results that accelerate research in functional genomics, disease modeling, and drug development.
Ramona Unveils Vireo™: The World’s Fastest Live-Cell Imaging System
DURHAM, N.C., Jan. 15, 2025 /PRNewswire/ — Ramona introduces groundbreaking Vireo™ live-cell imaging system, delivering 10x faster analysis for drug discovery workflows.
AGC Biologics to Manufacture LVV for CAR-T Therapy Approved by FDA for Autolus Therapeutics’ AUCATZYL®
AGC Biologics partners with Autolus Therapeutics to manufacture FDA-approved lentiviral vectors (LVV) for advanced CAR-T cancer therapies.
Ambient Biosciences Seeks Early Access Program Partners to Trial Room Temperature Stabilization Technology for Biomolecules and Reagents
Ambient Biosciences invites partners for trials of its room-temperature stabilization technology, revolutionizing biomolecule and reagent storage.
